Eagle Pharmaceuticals is a pharmaceutical company focused on treating diseases of the central nervous system or metabolic critical care therapeutic areas as well as in oncology. Co.'s products include: Ryanodex® for malignant hyperthermia, EP-4104 Ryanodex® (dantrolene sodium) for the treatment of organophosphate exposure, EP-5101 (PEMFEXY) for lung cancer, EGL-5385-C-1701 (fulvestrant) for breast cancer and Belrapzo and Bendeka for chronic lymphocytic leukemia and non-Hodgkin's lymphoma. Co.'s portfolio also consist of Vasopressin injection, which is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. The EGRX stock yearly return is shown above.
The yearly return on the EGRX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the EGRX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|